The needs of millions with rheumatic diseases throughout the 3rd world remain unmet & ignored. Read my article at https://t.co/3HwKTbI1BF
— Bharat Kumar (@BharatKumarMD) April 3, 2016
Last night, I took a long walk to clear my mind and gazed up at the night sky. On this moonless night, I saw the Milky Way in all its glory, something I only rarely get to appreciate nowadays. Seeing Orion, the Big Dipper, and the other constellations triggered some very fond memories of family vacations that we spent in India. I remember my grandfather pointing above to connect the dots and telling me the mythic stories of how they came to be in their positions in the night sky.
It also reminded me about how small our world is. The same stars that I viewed from the foothills of the Himalayas twenty-some-odd years ago are the same ones I can see from the plains of Midwestern America. And the same diseases that I see in clinic – Rheumatoid Arthritis and Systemic Lupus Erythematosus to name just two – are the same that afflict those throughout India and the third world.
But for some reason, we completely forget about those in the developing world who have these diseases. For some reason, we think that only the immune systems of those people in the First World are susceptible to dysregulation, and that, because we have effective treatments to induce remission in many of these patients, that poorly controlled disease is a thing of the past.
It’s not. The agents we use to induce remission are largely either unavailable or inappropriate in large swathes of the developing world. It’s unreasonable to use some of our potent immunosuppressants in areas where latent tuberculosis is rife. Monitoring for toxicity is often impossible, and so patients are left to suffer on their own.
This editorial is meant to help bring these issues to the forefront, and to highlight that our work, as rheumatologists and rheumatologists-in-training, is far from done. Immunologic and musculoskeletal diseases bear a disproportionately high rate of morbidity in these areas. It’s easy to get caught up in the excitement of new medications and diagnostic techniques, but we must never forget that we are also obligated to treat those with the greatest need.